Should adjuvant CRT be considered in gastric cancer patients who received pre-op chemo based on the recent results of the CRITICS trial?

There are many nuances here, but CRITICS suggests that there is little if any benefit to the routine use of postoperative chemoRT, in addition to pre- and post-op chemo, in resected gastric cancer patients who undergo a D2 dissection. The only scenario where I really consider postop CRT to be strong...